PRAMEF31P

Across TCGA pan-cancer cohorts, PRAMEF31P RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated PRAMEF31P data layer.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher PRAMEF31P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF31P expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

UCS, COAD, and DLBC are the cancer types where PRAMEF31P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Tertile	IV	0.132	0.718	.002	144	view →
COAD	OS	Tertile	All	0.027	0.871	<.001	36	view →
DLBC	OS	Tertile	III,IV	0.272	1.000	.017	31	view →
CESC	OS	Tertile	III,IV	0.167	0.657	.044	18	view →
KIRC	OS	Tertile	All	0.747	0.813	.017	18	view →
HNSC	DFS	Tertile	All	0.566	0.289	.010	12	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	9	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PRAMEF31P–UCS (DFS)

Open the UCS breakdown →